NICE批准默沙东的Keytruda用于治疗膀胱癌

2018-05-01 MedSci MedSci原创

英国国家卫生与保健优化研究所（NICE）批准默沙东（MSD）的PD-1免疫治疗药物Keytruda（pembrolizumab）用于治疗顺铂等化疗药物无效的局部晚期和转移尿路上皮癌患者。

英国国家卫生与保健优化研究所（NICE）批准默沙东（MSD）的PD-1免疫治疗药物Keytruda（pembrolizumab）用于治疗顺铂等化疗药物无效的局部晚期和转移尿路上皮癌患者。该决定是基于KEYNOTE-045的临床试验，该试验显示Keytruda比化疗药物延长了患者3个月的总生存期（中位生存期：Keytruda10.3个月，化疗7.4个月）。

"Fight Bladder Cancer"的创始人兼首席执行官Andrew Winterbottom表示："含顺铂的化疗通常是晚期膀胱癌患者的首选治疗方案，但许多患者由于一些临床参数的指标，并不适合该疗法。可是如果患者不进行化疗，基本就没有其他的治疗方案了。能够看到Keytruda这样的疗效真的是非常兴奋，新的治疗方法很可能为许多患者提供有意义的临床效果，并且患者通常能够很好的耐受，这是临床实践中的一个重大变化。

英国每年有超过10000人被诊断为膀胱癌，超过9000人患有尿路上皮癌，其中约540人现在可以从Keytruda的治疗中受益。

原始出处：

http://www.pharmatimes.com/news/final_nice_nod_for_keytruda_in_bladder_cancer_1233732

此文系梅斯医学（MedSci)原创整理编译，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (7)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=311524, encodeId=93853115245e, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 03 06:54:11 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259946, encodeId=00bb1259946ac, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Thu May 03 06:25:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289022, encodeId=5e39128902271, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Thu May 03 06:25:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311153, encodeId=152031115374, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRk75KAEKrLGic0S0IvH1aNynsEFQWiaNKdtzvtwj2kafCoPg2icYVbrfBCFiaS74X1uEiaaTTY1H9Xyem/0, createdBy=cec11614828, createdName=chunjianf, createdTime=Wed May 02 06:37:58 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311020, encodeId=ef0631102007, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Tue May 01 19:31:25 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311014, encodeId=2af13110142b, content=才三个月啊.有意思么, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cabb1969833, createdName=semrour, createdTime=Tue May 01 18:52:41 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310998, encodeId=35c531099866, content=又一个抗癌新药诞生了., beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue May 01 16:52:43 CST 2018, time=2018-05-01, status=1, ipAttribution=)]
2018-05-03 1209e435m98(暂无昵称)

学习了.谢谢分享

55 0
[GetPortalCommentsPageByObjectIdResponse(id=311524, encodeId=93853115245e, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 03 06:54:11 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259946, encodeId=00bb1259946ac, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Thu May 03 06:25:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289022, encodeId=5e39128902271, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Thu May 03 06:25:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311153, encodeId=152031115374, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRk75KAEKrLGic0S0IvH1aNynsEFQWiaNKdtzvtwj2kafCoPg2icYVbrfBCFiaS74X1uEiaaTTY1H9Xyem/0, createdBy=cec11614828, createdName=chunjianf, createdTime=Wed May 02 06:37:58 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311020, encodeId=ef0631102007, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Tue May 01 19:31:25 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311014, encodeId=2af13110142b, content=才三个月啊.有意思么, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cabb1969833, createdName=semrour, createdTime=Tue May 01 18:52:41 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310998, encodeId=35c531099866, content=又一个抗癌新药诞生了., beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue May 01 16:52:43 CST 2018, time=2018-05-01, status=1, ipAttribution=)]
2018-05-03 yese

#默沙东#

38 0
[GetPortalCommentsPageByObjectIdResponse(id=311524, encodeId=93853115245e, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 03 06:54:11 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259946, encodeId=00bb1259946ac, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Thu May 03 06:25:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289022, encodeId=5e39128902271, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Thu May 03 06:25:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311153, encodeId=152031115374, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRk75KAEKrLGic0S0IvH1aNynsEFQWiaNKdtzvtwj2kafCoPg2icYVbrfBCFiaS74X1uEiaaTTY1H9Xyem/0, createdBy=cec11614828, createdName=chunjianf, createdTime=Wed May 02 06:37:58 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311020, encodeId=ef0631102007, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Tue May 01 19:31:25 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311014, encodeId=2af13110142b, content=才三个月啊.有意思么, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cabb1969833, createdName=semrour, createdTime=Tue May 01 18:52:41 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310998, encodeId=35c531099866, content=又一个抗癌新药诞生了., beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue May 01 16:52:43 CST 2018, time=2018-05-01, status=1, ipAttribution=)]
2018-05-03 fusion

#NICE#

29 0
[GetPortalCommentsPageByObjectIdResponse(id=311524, encodeId=93853115245e, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 03 06:54:11 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259946, encodeId=00bb1259946ac, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Thu May 03 06:25:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289022, encodeId=5e39128902271, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Thu May 03 06:25:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311153, encodeId=152031115374, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRk75KAEKrLGic0S0IvH1aNynsEFQWiaNKdtzvtwj2kafCoPg2icYVbrfBCFiaS74X1uEiaaTTY1H9Xyem/0, createdBy=cec11614828, createdName=chunjianf, createdTime=Wed May 02 06:37:58 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311020, encodeId=ef0631102007, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Tue May 01 19:31:25 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311014, encodeId=2af13110142b, content=才三个月啊.有意思么, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cabb1969833, createdName=semrour, createdTime=Tue May 01 18:52:41 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310998, encodeId=35c531099866, content=又一个抗癌新药诞生了., beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue May 01 16:52:43 CST 2018, time=2018-05-01, status=1, ipAttribution=)]
2018-05-02 chunjianf

学习了.谢谢分享

0 0
[GetPortalCommentsPageByObjectIdResponse(id=311524, encodeId=93853115245e, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 03 06:54:11 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259946, encodeId=00bb1259946ac, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Thu May 03 06:25:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289022, encodeId=5e39128902271, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Thu May 03 06:25:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311153, encodeId=152031115374, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRk75KAEKrLGic0S0IvH1aNynsEFQWiaNKdtzvtwj2kafCoPg2icYVbrfBCFiaS74X1uEiaaTTY1H9Xyem/0, createdBy=cec11614828, createdName=chunjianf, createdTime=Wed May 02 06:37:58 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311020, encodeId=ef0631102007, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Tue May 01 19:31:25 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311014, encodeId=2af13110142b, content=才三个月啊.有意思么, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cabb1969833, createdName=semrour, createdTime=Tue May 01 18:52:41 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310998, encodeId=35c531099866, content=又一个抗癌新药诞生了., beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue May 01 16:52:43 CST 2018, time=2018-05-01, status=1, ipAttribution=)]
2018-05-01 changjiu

学习一下谢谢

77 0
[GetPortalCommentsPageByObjectIdResponse(id=311524, encodeId=93853115245e, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 03 06:54:11 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259946, encodeId=00bb1259946ac, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Thu May 03 06:25:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289022, encodeId=5e39128902271, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Thu May 03 06:25:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311153, encodeId=152031115374, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRk75KAEKrLGic0S0IvH1aNynsEFQWiaNKdtzvtwj2kafCoPg2icYVbrfBCFiaS74X1uEiaaTTY1H9Xyem/0, createdBy=cec11614828, createdName=chunjianf, createdTime=Wed May 02 06:37:58 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311020, encodeId=ef0631102007, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Tue May 01 19:31:25 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311014, encodeId=2af13110142b, content=才三个月啊.有意思么, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cabb1969833, createdName=semrour, createdTime=Tue May 01 18:52:41 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310998, encodeId=35c531099866, content=又一个抗癌新药诞生了., beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue May 01 16:52:43 CST 2018, time=2018-05-01, status=1, ipAttribution=)]
2018-05-01 semrour

才三个月啊.有意思么

65 0
[GetPortalCommentsPageByObjectIdResponse(id=311524, encodeId=93853115245e, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 03 06:54:11 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259946, encodeId=00bb1259946ac, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Thu May 03 06:25:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289022, encodeId=5e39128902271, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Thu May 03 06:25:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311153, encodeId=152031115374, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRk75KAEKrLGic0S0IvH1aNynsEFQWiaNKdtzvtwj2kafCoPg2icYVbrfBCFiaS74X1uEiaaTTY1H9Xyem/0, createdBy=cec11614828, createdName=chunjianf, createdTime=Wed May 02 06:37:58 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311020, encodeId=ef0631102007, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Tue May 01 19:31:25 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311014, encodeId=2af13110142b, content=才三个月啊.有意思么, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cabb1969833, createdName=semrour, createdTime=Tue May 01 18:52:41 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310998, encodeId=35c531099866, content=又一个抗癌新药诞生了., beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue May 01 16:52:43 CST 2018, time=2018-05-01, status=1, ipAttribution=)]
2018-05-01 1e0f8808m18(暂无匿称)

又一个抗癌新药诞生了.

63 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科

NICE批准默沙东的Keytruda用于治疗膀胱癌

相关资讯

科室

工具

服务